Effect of Ectoin® Inhalation Solution on Subjects With Mild Bronchial Asthma

Inclusion Criteria: * Adults (18 - 65 years) * FEV1 ≥ 80% of predicted for patient's normal value pre bronchodilator (according to European Coal and Steel Community reference values) * Positive Methacholine challenge test (PD20 ≤ 0.5 mg) * A general practitioner or consultant diagnosed mild bronchial asthma * Non or ex smoker (for more than 6 months, pack years (PY) ≤ 5) Exclusion Criteria: * Pregnant or lactating females * Participation in another clinical study in the previous month * Severe concomitant disease which may have an impact on the study participation * Hypersensibility against Ectoin® * Patients who have had treatment with live attenuated vaccinations within 14 days prior to screening visit (Inactivated influenza vaccination is acceptable, provided it is not administered within 7 days prior to screening visit). * Other respiratory diseases (e.g. Chronic obstructive pulmonary disease (COPD), cystic fibrosis, alpha-1-Antitrypsin deficiency, sarcoidosis, bronchiectasis, allergic alveolitis, tuberculosis, etc.) * Upper and lower airway respiratory infection within 4 weeks prior to study start